자율신경실조증 시장 규모는 향후 수년간 급성장이 전망됩입니다. 2029년에는 CAGR 11.5%로 성장할 전망이며, 45억 3,000만 달러로 성장이 예측됩니다. 예측 기간 동안 성장은 맞춤형 의료의 채용 증가, 신규 치료법 임상시험 증가, 희귀질환 연구에 대한 정부 자금 증가, 원격의료 및 원격 모니터링 솔루션 확대, 희귀 의약품 이용 가능성 확대 등의 요인에 의한 것으로 보입니다. 이 기간에 예상되는 주요 동향으로는 진단에서 인공지능 통합, 표적 치료 개발, 자율신경 모니터링을 위한 웨어러블 디바이스 사용, 유전자 치료의 진보, 환자 중심의 치료 접근법 혁신 등이 있습니다.
만성질환의 유병률 상승은 자율신경실조증 시장의 성장을 가속할 것으로 예측됩니다. 만성질환은 3개월 이상 지속되는 장기적인 질환이며, 그 증가는 개인이 여러 만성질환과 동시에 진단받는 다질환 병존증(multimorbidity) 증가 등의 요인과 관련되어 있습니다. 자율신경실조증은 심박수, 혈압, 소화 등의 중요한 기능을 조절하는 신체의 능력을 장애함으로써 이러한 질환에서 중요한 역할을 하며, 종종 증상을 악화시키고 치료를 복잡하게 합니다. 예를 들어 2023년 10월 영국의 국민보건서비스(National Health Service)는 잉글랜드의 1형 당뇨병 유병률이 2020-2021년 261,710례에서 2021-2022년 270,935례로 증가하여 전년 대비 3.5% 증가했다고 보고했습니다. 만성질환이 보편화됨에 따라 자율신경실조증 시장의 확대가 예상됩니다.
자가면역질환과 신경질환 증가도 시장 성장의 원동력이 될 것으로 예측됩니다. 자가면역질환 및 신경질환은 면역계가 실수로 신경계를 공격하여 뇌, 척수, 말초신경에 염증, 손상, 기능장애를 일으키면서 발병합니다. 이러한 증가는 유전적 소인, 환경적 유인, 라이프 스타일의 변화, 감염, 진단 기술의 향상 등의 요인에 의한 것입니다. 모그렌증후군, 다발성경화증, 파킨슨병, 다계통위축증(MSA) 등의 질환에서 자율신경실조증의 존재는 종종 이러한 질환의 중요한 지표가 됩니다. 예를 들어 2023년 7월 스코틀랜드 공중보건국은 2022년 새로 다발성 경화증으로 진단된 환자 수가 87.2% 증가해 491명의 신규 사례가 보고돼 총 6,359명이 됐다고 보고했습니다. 자가면역질환과 신경질환의 증가에 따라 자율신경실조증 시장은 앞으로도 계속 성장할 것으로 예상됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 자율신경실조증 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 자율신경실조증 시장 : 성장률 분석
- 세계의 자율신경실조증 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 자율신경실조증 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 자율신경실조증 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 자율신경실조증 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 신경성 기립성 저혈압(NOH)
- 기립성 조절 장애(POTS)
- 다계통 위축증(MSA)
- 순수자율신경부전증(PAF)
- 기타 유형
- 세계의 자율신경실조증 시장 : 검사별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 심장 미주 신경 및 혈관 운동 기능 검사
- 체온조절 발한 검사(TST)
- 교감 신경성 피부 반응(SSR)
- 정량적 발한 운동 축삭 반사 검사
- 기타 검사
- 세계의 자율신경실조증 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 물리치료
- 운동요법
- 상담
- 기타 치료법
- 세계의 자율신경실조증 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원 약국
- 온라인 약국
- 소매 약국
- 세계의 자율신경실조증 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 클리닉
- 진단센터
- 연구기관
- 세계의 자율신경실조증 시장 : 신경성 기립성 저혈압증(NOH) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 1차 NOH
- 2차 NOH(파킨슨병, 당뇨병 등에 의한)
- NOH의 약리학적 관리
- 비약리학적 개입
- 세계의 자율신경실조증 시장 : 체위성 기립성 빈맥 증후군(POTS) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 고아드레날린성 POTS
- 저용량성 POTS
- 신경장애성 POTS
- 자가면역 POTS
- 베타 차단제, 플루드로 코르티손, 염분 보급에 의한 치료
- 세계의 자율신경실조증 시장 : 다계통 위축증(MSA) 병형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- MSA-P(파킨슨병)
- MSA-C(소뇌)
- MSA-A(자율 신경계)
- 질환 수식 및 치료
- 세계의 자율신경실조증 시장 : 순수자율신경부전증(PAF) 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 특발성 PAF
- 이차성 PAF(신경퇴행성 질환에 의한)
- 자율신경지지요법
- 세계의 자율신경실조증 시장 : 기타 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 가족성 자율신경실조증(FD)
- 당뇨병성 자율신경장애
- 호르넬 증후군
- 자가면역성 자율신경절증
- 만성 피로 증후군 관련 자율신경실조증
제7장 지역별 및 국가별 분석
- 세계의 자율신경실조증 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 자율신경실조증 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 자율신경실조증 시장 : 경쟁 구도
- 자율신경실조증 시장 : 기업 프로파일
- Teva Pharmaceutical Industries Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
- H. Lundbeck A/S 개요, 제품 및 서비스, 전략 및 재무 분석
- Aurobindo Pharma Limited 개요, 제품 및 서비스, 전략 및 재무 분석
- Hikma Pharmaceuticals PLC 개요, 제품 및 서비스, 전략 및 재무 분석
- Cadila Healthcare Limited(Zydus Cadila)개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Lupin Limited
- Nemours Children's Health Delaware
- Alnylam Pharmaceuticals Inc.
- Biohaven Pharmaceuticals Holding Company Ltd.
- Aurora Health Care Inc.
- Camber Pharmaceuticals Inc.
- Theravance Biopharma Inc.
- Tocris Bioscience
- Celltex Therapeutics Corporation
- DyAnsys Inc.
- Axplora Inc.
- MODAG GmbH
- Inhibikase Therapeutics Inc.
- Mylan Pharmaceuticals Private Limited
- Chelsea Therapeutics International Ltd.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 자율신경실조증 시장(2029년) : 새로운 기회를 제공하는 국가
- 자율신경실조증 시장(2029년) : 새로운 기회를 제공하는 부문
- 자율신경실조증 시장(2029년) : 성장 전략
제36장 부록
AJY
Dysautonomia, or autonomic dysfunction, refers to a condition in which the autonomic nervous system (ANS) malfunctions, affecting involuntary bodily functions such as heart rate, blood pressure, digestion, and temperature regulation. It can be caused by various factors such as genetic predispositions, injuries, or underlying health conditions, leading to symptoms such as dizziness, fainting, and irregular heartbeats.
The primary types of dysautonomia (autonomic dysfunction) include neurogenic orthostatic hypotension (NOH), postural orthostatic tachycardia syndrome (POTS), multiple system atrophy (MSA), pure autonomic failure (PAF), and other forms. Neurogenic orthostatic hypotension occurs due to autonomic nervous system dysfunction, causing a significant drop in blood pressure when standing, which results in dizziness, lightheadedness, and fainting. Diagnosing dysautonomia involves tests such as cardiovagal and vasomotor function assessments, the thermoregulatory sweat test (TST), sympathetic skin response (SSR), and the quantitative sudomotor axon reflex test, among others. Treatment options include physical therapy, exercise therapy, counseling, and other therapeutic interventions. Medications and treatments are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, with key end users being hospitals, clinics, diagnostic centers, and research institutes.
The dysautonomia (autonomic dysfunction) market research report is one of a series of new reports from The Business Research Company that provides dysautonomia (autonomic dysfunction) market statistics, including the dysautonomia (autonomic dysfunction) industry global market size, regional shares, competitors with the dysautonomia (autonomic dysfunction) market share, detailed dysautonomia (autonomic dysfunction) market segments, market trends, and opportunities, and any further data you may need to thrive in the dysautonomia (autonomic dysfunction) industry. This dysautonomia (autonomic dysfunction) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The dysautonomia (autonomic dysfunction) market size has grown rapidly in recent years. It will grow from $2.62 billion in 2024 to $2.92 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth during the historic period can be attributed to factors such as the rising prevalence of autonomic disorders, greater awareness of dysautonomia, increased healthcare spending, expanding research into neurodegenerative diseases, and growing government support for rare diseases.
The dysautonomia (autonomic dysfunction) market size is expected to see rapid growth in the next few years. It will grow to $4.53 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth during the forecast period can be attributed to factors such as the increasing adoption of personalized medicine, a rise in clinical trials for novel treatments, growing government funding for rare disease research, the expansion of telemedicine and remote monitoring solutions, and greater availability of orphan drugs. Key trends expected in this period include the integration of artificial intelligence in diagnostics, the development of targeted therapies, the use of wearable devices for autonomic monitoring, advancements in gene therapies, and innovation in patient-centric treatment approaches.
The rising prevalence of chronic diseases is expected to drive the growth of the dysautonomia (autonomic dysfunction) market. Chronic diseases are long-lasting conditions that persist for more than three months, and their increase is linked to factors such as the growing occurrence of multimorbidity, where individuals are diagnosed with multiple chronic disorders simultaneously. Dysautonomia plays a significant role in these conditions by disrupting the body's ability to regulate critical functions such as heart rate, blood pressure, and digestion, often worsening symptoms and complicating treatment. For example, in October 2023, the National Health Service in the UK reported that the prevalence of Type 1 diabetes in England rose from 261,710 cases in 2020-21 to 270,935 cases in 2021-22, marking a 3.5% increase year-over-year. As chronic diseases become more common, the dysautonomia market is expected to expand.
The growing number of autoimmune and neurological disorders is also expected to drive market growth. Autoimmune and neurological disorders occur when the immune system mistakenly attacks the nervous system, causing inflammation, damage, and dysfunction in the brain, spinal cord, or peripheral nerves. This increase is attributed to factors such as genetic predisposition, environmental triggers, lifestyle changes, infections, and better diagnostic techniques. Dysautonomia is often a key indicator of these disorders, as its presence in conditions such as Sj?gren's syndrome, multiple sclerosis, Parkinson's disease, and multiple system atrophy (MSA) helps doctors identify, monitor, and manage disease progression and create more targeted treatments. For instance, in July 2023, Public Health Scotland reported that the number of newly diagnosed multiple sclerosis patients rose by 87.2% in 2022, with 491 new cases reported, bringing the total to 6,359. As autoimmune and neurological disorders increase, the dysautonomia market is expected to continue growing.
Companies are focusing on developing new treatments using recombinant adeno-associated viruses (rAAV) to deliver therapeutic genes to target cells more effectively. rAAV is a modified virus used in gene therapy to introduce genetic material into cells without causing disease. For example, in January 2025, Tikun Therapeutics Inc., a U.S.-based biotechnology company, received FDA approval for Orphan Drug and Rare Pediatric Disease Designations for its gene therapy treatments rAAV2-U1a-hELP1, designed for optic neuropathy in familial dysautonomia, and BPN-36964, a small molecule splicing modulator for systemic FD treatment. These therapies aim to address the genetic causes of familial dysautonomia, offering long-term benefits beyond symptomatic treatment.
Major players in the dysautonomia (autonomic dysfunction) market are Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Cadila Healthcare Limited (Zydus Cadila), Lupin Limited, Nemours Children's Health Delaware, Alnylam Pharmaceuticals Inc., Biohaven Pharmaceuticals Holding Company Ltd., Aurora Health Care Inc., Camber Pharmaceuticals Inc., Theravance Biopharma Inc., Tocris Bioscience a subsidiary of Bio-Techne Corporation, Celltex Therapeutics Corporation, DyAnsys Inc., Axplora Inc., MODAG GmbH, Inhibikase Therapeutics Inc., Mylan Pharmaceuticals Private Limited, Chelsea Therapeutics International Ltd.
North America was the largest region in the dysautonomia (autonomic dysfunction) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dysautonomia (autonomic dysfunction) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the dysautonomia (autonomic dysfunction) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dysautonomia (autonomic dysfunction) market consists of revenues earned by entities by providing services such as pharmaceutical treatment, radiation therapy, diagnostic services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The dysautonomia (autonomic dysfunction) market also includes sales of diagnostic tools, intravenous therapies, neurostimulatory devices, compression garments, and electrolyte supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Dysautonomia (Autonomic Dysfunction) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on dysautonomia (autonomic dysfunction) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for dysautonomia (autonomic dysfunction) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dysautonomia (autonomic dysfunction) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Neurogenic Orthostatic Hypotension (NOH); Postural Orthostatic Tachycardia Syndrome (POTS); Multiple System Atrophy (MSA); Pure Autonomic Failure (PAF); Other Types
- 2) By Tests: Cardiovagal and Vasomotor Function Tests; Thermoregulatory Sweat Test (TST); Sympathetic Skin Response (SSR); Quantitative Sudomotor Axon Reflex Test; Other Tests
- 3) By Treatment: Physical Therapy; Exercise Therapy; Counseling; Other Treatments
- 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
- 5) By End User: Hospitals; Clinics; Diagnostic Centers; Research Institutes
- Subsegments:
- 1) By Neurogenic Orthostatic Hypotension (NOH): Primary NOH; Secondary NOH (due to Parkinson's Disease, Diabetes, etc.); Pharmacological Management of NOH; Non-Pharmacological Interventions
- 2) By Postural Orthostatic Tachycardia Syndrome (POTS): Hyperadrenergic POTS; Hypovolemic POTS; Neuropathic POTS; Autoimmune POTS; Treatment With Beta-Blockers, Fludrocortisone, And Salt Supplements
- 3) By Multiple System Atrophy (MSA): MSA-P (Parkinsonism); MSA-C (Cerebellar); MSA-A (Autonomic); Disease-Modifying and Symptomatic Treatment
- 4) By Pure Autonomic Failure (PAF): Idiopathic PAF; Secondary PAF (due to neurodegenerative diseases); Autonomic Supportive Treatments
- 5) By Other Types: Familial Dysautonomia (FD); Diabetic Autonomic Neuropathy; Horner's Syndrome; Autoimmune Autonomic Ganglionopathy; Chronic Fatigue Syndrome-related Dysautonomia
- Companies Mentioned: Teva Pharmaceutical Industries Ltd.; H. Lundbeck A/S; Aurobindo Pharma Limited; Hikma Pharmaceuticals PLC; Cadila Healthcare Limited (Zydus Cadila)
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Dysautonomia (Autonomic Dysfunction) Market Characteristics
3. Dysautonomia (Autonomic Dysfunction) Market Trends And Strategies
4. Dysautonomia (Autonomic Dysfunction) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Dysautonomia (Autonomic Dysfunction) Growth Analysis And Strategic Analysis Framework
- 5.1. Global Dysautonomia (Autonomic Dysfunction) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Dysautonomia (Autonomic Dysfunction) Market Growth Rate Analysis
- 5.4. Global Dysautonomia (Autonomic Dysfunction) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Dysautonomia (Autonomic Dysfunction) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Dysautonomia (Autonomic Dysfunction) Total Addressable Market (TAM)
6. Dysautonomia (Autonomic Dysfunction) Market Segmentation
- 6.1. Global Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Neurogenic Orthostatic Hypotension (NOH)
- Postural Orthostatic Tachycardia Syndrome (POTS)
- Multiple System Atrophy (MSA)
- Pure Autonomic Failure (PAF)
- Other Types
- 6.2. Global Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Cardiovagal and Vasomotor Function Tests
- Thermoregulatory Sweat Test (TST)
- Sympathetic Skin Response (SSR)
- Quantitative Sudomotor Axon Reflex Test
- Other Tests
- 6.3. Global Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Physical Therapy
- Exercise Therapy
- Counseling
- Other Treatments
- 6.4. Global Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- 6.5. Global Dysautonomia (Autonomic Dysfunction) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Diagnostic Centers
- Research Institutes
- 6.6. Global Dysautonomia (Autonomic Dysfunction) Market, Sub-Segmentation Of Neurogenic Orthostatic Hypotension (NOH), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Primary NOH
- Secondary NOH (due to Parkinson's Disease, Diabetes, etc.)
- Pharmacological Management of NOH
- Non-Pharmacological Interventions
- 6.7. Global Dysautonomia (Autonomic Dysfunction) Market, Sub-Segmentation Of Postural Orthostatic Tachycardia Syndrome (POTS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hyperadrenergic POTS
- Hypovolemic POTS
- Neuropathic POTS
- Autoimmune POTS
- Treatment With Beta-Blockers, Fludrocortisone, And Salt Supplements
- 6.8. Global Dysautonomia (Autonomic Dysfunction) Market, Sub-Segmentation Of Multiple System Atrophy (MSA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- MSA-P (Parkinsonism)
- MSA-C (Cerebellar)
- MSA-A (Autonomic)
- Disease-Modifying and Symptomatic Treatment
- 6.9. Global Dysautonomia (Autonomic Dysfunction) Market, Sub-Segmentation Of Pure Autonomic Failure (PAF), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Idiopathic PAF
- Secondary PAF (due to neurodegenerative diseases)
- Autonomic Supportive Treatments
- 6.10. Global Dysautonomia (Autonomic Dysfunction) Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Familial Dysautonomia (FD)
- Diabetic Autonomic Neuropathy
- Horner's Syndrome
- Autoimmune Autonomic Ganglionopathy
- Chronic Fatigue Syndrome-related Dysautonomia
7. Dysautonomia (Autonomic Dysfunction) Market Regional And Country Analysis
- 7.1. Global Dysautonomia (Autonomic Dysfunction) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Dysautonomia (Autonomic Dysfunction) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Dysautonomia (Autonomic Dysfunction) Market
- 8.1. Asia-Pacific Dysautonomia (Autonomic Dysfunction) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Dysautonomia (Autonomic Dysfunction) Market
- 9.1. China Dysautonomia (Autonomic Dysfunction) Market Overview
- 9.2. China Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Dysautonomia (Autonomic Dysfunction) Market
- 10.1. India Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Dysautonomia (Autonomic Dysfunction) Market
- 11.1. Japan Dysautonomia (Autonomic Dysfunction) Market Overview
- 11.2. Japan Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Dysautonomia (Autonomic Dysfunction) Market
- 12.1. Australia Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Dysautonomia (Autonomic Dysfunction) Market
- 13.1. Indonesia Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Dysautonomia (Autonomic Dysfunction) Market
- 14.1. South Korea Dysautonomia (Autonomic Dysfunction) Market Overview
- 14.2. South Korea Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Dysautonomia (Autonomic Dysfunction) Market
- 15.1. Western Europe Dysautonomia (Autonomic Dysfunction) Market Overview
- 15.2. Western Europe Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Dysautonomia (Autonomic Dysfunction) Market
- 16.1. UK Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Dysautonomia (Autonomic Dysfunction) Market
- 17.1. Germany Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Dysautonomia (Autonomic Dysfunction) Market
- 18.1. France Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Dysautonomia (Autonomic Dysfunction) Market
- 19.1. Italy Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Dysautonomia (Autonomic Dysfunction) Market
- 20.1. Spain Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Dysautonomia (Autonomic Dysfunction) Market
- 21.1. Eastern Europe Dysautonomia (Autonomic Dysfunction) Market Overview
- 21.2. Eastern Europe Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Dysautonomia (Autonomic Dysfunction) Market
- 22.1. Russia Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Dysautonomia (Autonomic Dysfunction) Market
- 23.1. North America Dysautonomia (Autonomic Dysfunction) Market Overview
- 23.2. North America Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Dysautonomia (Autonomic Dysfunction) Market
- 24.1. USA Dysautonomia (Autonomic Dysfunction) Market Overview
- 24.2. USA Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Dysautonomia (Autonomic Dysfunction) Market
- 25.1. Canada Dysautonomia (Autonomic Dysfunction) Market Overview
- 25.2. Canada Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Dysautonomia (Autonomic Dysfunction) Market
- 26.1. South America Dysautonomia (Autonomic Dysfunction) Market Overview
- 26.2. South America Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Dysautonomia (Autonomic Dysfunction) Market
- 27.1. Brazil Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Dysautonomia (Autonomic Dysfunction) Market
- 28.1. Middle East Dysautonomia (Autonomic Dysfunction) Market Overview
- 28.2. Middle East Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Dysautonomia (Autonomic Dysfunction) Market
- 29.1. Africa Dysautonomia (Autonomic Dysfunction) Market Overview
- 29.2. Africa Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Tests, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Dysautonomia (Autonomic Dysfunction) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Dysautonomia (Autonomic Dysfunction) Market Competitive Landscape And Company Profiles
- 30.1. Dysautonomia (Autonomic Dysfunction) Market Competitive Landscape
- 30.2. Dysautonomia (Autonomic Dysfunction) Market Company Profiles
- 30.2.1. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. H. Lundbeck A/S Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Hikma Pharmaceuticals PLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Cadila Healthcare Limited (Zydus Cadila) Overview, Products and Services, Strategy and Financial Analysis
31. Dysautonomia (Autonomic Dysfunction) Market Other Major And Innovative Companies
- 31.1. Lupin Limited
- 31.2. Nemours Children's Health Delaware
- 31.3. Alnylam Pharmaceuticals Inc.
- 31.4. Biohaven Pharmaceuticals Holding Company Ltd.
- 31.5. Aurora Health Care Inc.
- 31.6. Camber Pharmaceuticals Inc.
- 31.7. Theravance Biopharma Inc.
- 31.8. Tocris Bioscience
- 31.9. Celltex Therapeutics Corporation
- 31.10. DyAnsys Inc.
- 31.11. Axplora Inc.
- 31.12. MODAG GmbH
- 31.13. Inhibikase Therapeutics Inc.
- 31.14. Mylan Pharmaceuticals Private Limited
- 31.15. Chelsea Therapeutics International Ltd.
32. Global Dysautonomia (Autonomic Dysfunction) Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Dysautonomia (Autonomic Dysfunction) Market
34. Recent Developments In The Dysautonomia (Autonomic Dysfunction) Market
35. Dysautonomia (Autonomic Dysfunction) Market High Potential Countries, Segments and Strategies
- 35.1 Dysautonomia (Autonomic Dysfunction) Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Dysautonomia (Autonomic Dysfunction) Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Dysautonomia (Autonomic Dysfunction) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
